Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis

Novartis International AG / Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

• Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2]
   

In rheumatology, Cosentyx is now the most prescribed biologic therapy in the US for PsA patients starting or switching biologic agents[3]
 

New data follow five-year data in psoriasis, reinforcing unique position of Cosentyx as a long-lasting comprehensive treatment across multiple indications[4]

Basel, October 16, 2018 - Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx (secukinumab) in patients with psoriatic arthritis (PsA)[1] and ankylosing spondylitis (AS)[2] respectively. These new data will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, United States.

"AS and PsA have a significant impact on the quality of patients' lives, and they require a comprehensive treatment which targets all of the manifestations of their disease," said Professor Georg A. Schett, Professor and Chair, Department of Medicine, Rheumatology and Immunology at University of Erlangen-Nuremberg. "The presentation of long-term data in PsA and AS supports the central role of Cosentyx in the long-term sustained management of these complex and multi-faceted conditions."

New long-term data from FUTURE 1 and MEASURE 1 confirm that Cosentyx provides sustained improvements in the signs and symptoms of PsA and AS out to five years[1],[2]. In FUTURE 1, 83% and 94% of PsA patients achieved total resolution of enthesitis and dactylitis, respectively[1]. Over 80% of patients who entered the extension phases of both studies completed five years[1],[2], with a safety profile consistent with previous reports[4]-[6]. These data add to findings from the SCULPTURE study, in which two thirds of patients on Cosentyx reported no impact of skin disease on their quality of life over five years[4].